What Has Been the Growth Trajectory of the Cell and Gene Therapy Market?
The cell and gene therapy market has seen considerable growth due to a variety of factors.
• The size of the cell and gene therapy market has seen significant growth in the last few years. It is projected to expand from $12.01 billion in 2024 to $15.48 billion in 2025, with a compound annual growth rate (CAGR) hitting 28.9%.
This considerable growth during the historic period can be credited to heightened investment in cell and gene treatments, expansion in research and development, breakthroughs in the discovery of cancer drugs, a surge in public-private partnerships, robust economic progress in emerging markets, increased healthcare spending, and a rise in pharmaceutical R&D expenditure.
What Can Be Expected from the Cell and Gene Therapy Market in the Coming Years?
The cell and gene therapy market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated swift expansion is on the cards for the cell and gene therapy market in the coming years, with a value predicted to surge to $29.15 billion by 2029, nurtured by a 17.1% compound annual growth rate (CAGR).
The substantial growth anticipated within the forecast period can primarily be ascribed to mounting instances of cancer and persistent diseases, a growing geriatric demographic, increased attention on cell and gene therapy and amplified healthcare expenditure. Significant trends projected within this period encompass prioritizing sophisticated therapies like chimeric antigen receptor (CAR) T-cell treatment, focusing on initiating varied research endeavors and securing financing, performing strategic collaborations for the incorporation of cutting-edge technologies, investing in the development of gene or genome editing tools, particularly CRISPR, partnerships or acquisitions of rival companies, escalating the tally of pipeline studies for the evolution of cell and gene therapies, and the expansion of manufacturing facilities.
What Are the Critical Driver Fuelling the Cell and Gene Therapy Market's Growth?
The cell and gene therapy (CGT) market experienced growth due to consistent investment and amalgamation in cell and gene therapies. The potential of the CGT market took hold, with 16 out of the 20 leading biopharmaceutical companies by revenue incorporating CGT products into their collection. Specifically, in the year 2023, British cell and gene therapy corporations managed to secure over 55% of the venture capital funding collected by European businesses, as reported by the BioIndustry Association (BIA), a UK organization acting as a representative for the biotech and life sciences industries. Typically, the UK is responsible for about one-third of all venture capital investments in European life sciences, demonstrating the power of its cell and gene therapy industry. Stable investment and merging in CGT production facilitated an uptick in production capability, thereby fuelling market growth. For example, in October 2024, Purespring Therapeutics, a British biotechnology firm, acquired funding of $105 million which was directed towards the development of gene therapies for kidney diseases, involving a phase 1/2 trial targeting a potential treatment for immunoglobulin A nephropathy (IgAN). Purespring uses adeno-associated viruses (AAVs) as a mode of delivery for its gene therapies.
How Are The Segments Defined Within The Global Cell and Gene Therapy Market?
The cell and gene therapy market covered in this report is segmented –
1) By Product: Cell Therapy, Gene Therapy
2) By Application: Oncology, Neurological Disorders, Other Applications
3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users
Subsegments:
1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy
2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy
Pre-Book The Cell and Gene Therapy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Cell and Gene Therapy Market?
The cell and gene therapy (CGT) market is being significantly influenced by the development of Chimeric antigen receptor (CAR) T-cell therapy. This therapy blends cell and gene treatment, whereby T cells are extracted from the patient's blood and manipulated genetically to create altered receptors, referred to as chimeric antigen receptors (CARs), on their surface. The engineered T cells, furnished with unique receptors, are then reintroduced into the patient's body. Subsequently, these modified T cell receptors aim at the surface antigen of the cancer cell, resulting in the eradication of tumor cells. For example, Bristol-Myers Squibb Company, an American pharmaceutical firm, got clearance from the United States Food and Drug Administration (US FDA) in June 2022, for their CAR T cell therapy Breyanzi. Breyanzi is employed in treating adult patients battling from large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi is a distinctive CAR T cell therapy that is formulated from the patient's T cells, which are harvested and genetically reformulated to transform into CAR T cells before being rebroadcast as a singular treatment via infusion.
Who Are the Key Players in the Cell and Gene Therapy Market?
Major companies operating in the cell and gene therapy market include:
• Biogen Inc.
• Novartis AG
• Gilead Sciences
• Ionis Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• ArrowHead Pharmaceuticals Inc.
• Spark Therapeutics
• Bluebird Bio Inc.
• RegenexBio
• Mesoblast Limited
• Biocon
• Cipla
• Stempeutics Research Pvt. Ltd.
• EdiGene Inc.
• Immunochina
• Takara Bio
• Daiichi Sankyo Company
• Ultragenyx Pharmaceutical Inc
• Mitsubishi Tanabe Pharma
• Oxford Biomedica plc
• Santen Pharmaceutical Co.
• Therapeutic Innovation Australia
• Merck
• GenScript
• Cellular Biomedicine Group
• GE Healthcare
• inStem
• Lonza
• Nikon CeLL innovation Co. Ltd.
• Bristol-Myers Squibb
• Amgen
• Pfizer
• Kite Pharma
• Oxford BioTherapeutics
• Freeline Therapeutics
• PsiOxus Therapeutics
• Herantis Pharma Plc
• AstraZeneca
What Is The Most Dominant Region In The Cell and Gene Therapy Market?
North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
